ici 118551 and Central Nervous System Neoplasm

ici 118551 has been researched along with Central Nervous System Neoplasm in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aguirre, DT; Albiñana, V; Botella, LM; Cuesta, AM; de Las Heras, KVG; de Rojas-P, I; Gallardo-Vara, E; Recio-Poveda, L	1

Other Studies

1 other study(ies) available for ici 118551 and Central Nervous System Neoplasm

Article	Year
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. Scientific reports, 2019, 07-11, Volume: 9, Issue:1 Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Nucleus; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Propanolamines; Signal Transduction; Tumor Cells, Cultured; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein	2019

Article

Year

The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.

Scientific reports, 2019, 07-11, Volume: 9, Issue:1

Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Nucleus; Central Nervous System Neoplasms; Hemangioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Propanolamines; Signal Transduction; Tumor Cells, Cultured; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein

2019